Alper Üreten is vice president Commercialization, Program and Portfolio Management for Amgen. He is responsible for driving Amgen’s commercialization strategy for pipeline and marketed projects globally.

Üreten has more than 20 years of experience in the healthcare pharmaceutical sector across multiple functions and geographies. Prior to his current role, he was the vice president and general manager of Amgen’s Biosimilars Business Unit. Before that, he served as vice president and general manager of Amgen’s Türkiye, Middle East and Africa sub-region. Üreten joined Amgen in 2014 as the general manager of Amgen Türkiye.

Prior to joining Amgen, Üreten spent over 16 years with Bristol Myers Squibb (BMS) where he held positions of increasing responsibility in multiple countries and regions, including the Middle East, Türkiye, Russia and Africa, and in functions including finance and brand commercialization.

Üreten holds a B.S. in Civil Engineering from the Bosphorus University in Istanbul, and an MBA in Finance from the Golden Gate University in San Francisco.